Sign in
AADI Stock Price, Chart, Stats & News
Aadi Bioscience, Inc.
Save
94.89M
Market cap
–
Current P/E
–
Forward P/E
AADI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 89.36% |
Operating margin | -1601.12% |
Pretax margin | -288.26% |
Net margin | -288.26% |
Effective tax rate | – |
ROA | -13.66% |
ROE | -11.99% |
D/E | – |
Interest coverage ratio | – |
AADI valuation
P/E | – |
P/S | 13.28x |
P/B | 9.31x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | -0.15x |
EV multiple | -5.45x |
About
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing highly targeted therapies for cancers defined by specific genetic alterations within the mTOR pathway. Its flagship drug candidate, FYARRO, is an investigational therapeutic composed of sirolimus conjugated with albumin. Aadi is actively evaluating FYARRO's efficacy in various malignancies that exhibit known mTOR pathway activation.
Similar securities
Based on sector and market capitalization
Report issue